Spots Global Cancer Trial Database for A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Official Title: A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Study ID: NCT02600897
Study Description
Brief Summary: This study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment with obinutuzumab, polatuzumab vedotin, and lenalidomide in participants with relapsed or refractory (R/R) follicular lymphoma (FL) and rituximab in combination with polatuzumab vedotin and lenalidomide in participants with R/R diffuse large B-cell lymphoma (DLBCL), followed by post-induction treatment with obinutuzumab in combination with lenalidomide in participants with FL who achieve a complete response (CR), partial response (PR), or stable disease (SD) at end of induction (EOI) and post-induction treatment with rituximab plus lenalidomide in participants with DLBCL who achieve a CR or PR at EOI.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Marietta, Georgia, United States
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
University of Missouri/Ellis Fischel, Columbia, Missouri, United States
Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, United States
NYU School of Medicine, New York, New York, United States
Rocky Mountain Cancer Centers, LLP, Irving, Texas, United States
Texas Oncology-Tyler, Irving, Texas, United States
Texas Oncology San Antonio Medical Center, San Antonio, Texas, United States
Insititut Catala D'Oncologia, Hospitalet de Llobregat, Barcelona, Spain
Hospital Clínico Málaga, Málaga, Malaga, Spain
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
Clínica Universidad de Navarra, Pamplona, Navarra, Spain
Hospital Universitari Vall d'Hebron, Barcelona, , Spain
Hospital Clínic. Barcelona, Barcelona, , Spain
Hospital Santa Creu i Sant Pau, Barcelona, , Spain
Hospital Gregorio Marañon, Madrid, , Spain
H. Universitario Leonor, Madrid, , Spain
Hospital Universitario Fundacion Jimenez Diaz., Madrid, , Spain
Hospital La Fe, Valencia, , Spain
St James University Hospital, Leeds, , United Kingdom
University Hospitals of Leicester NHS Trust - Leicester Royal Infirmary, Leicester, , United Kingdom
Royal Liverpool University Hospital, Liverpool, , United Kingdom
Barts Hospital; Institute of Cancer, London, , United Kingdom
Sarah Cannon Research Institute, London, , United Kingdom
Maidstone & Tonbridge Wells Hospital; Kent Oncology Center, Maidstone, , United Kingdom
Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, , United Kingdom
Barking, Havering and Redbridge University Hospitals NHS Trust - Queen's Hospital, Romford, , United Kingdom
The Royal Wolverhampton Hospitals NHS Trust; Department of Haematology, Wolverhampton, , United Kingdom
Contact Details
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
